Loading...
Midatech Pharma plc
MTPH.L•LSE
Healthcare
Biotechnology
£18.00
£17.05(1794.74%)

Over the last four quarters, Midatech Pharma plc's revenue moved from $0.00 in Q2 2016 to $0.00 in Q2 2024. Operating income in Q2 2024 was -$4.22M, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Midatech Pharma plc remained robust at -$4.16M, reflecting operational efficiency. Net income dropped to -$3.31M, with an EPS of -$10.08. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan